Lb Pharmaceuticals (LBRX) Change in Acquisitions & Divestments (2024 - 2025)
Lb Pharmaceuticals' (LBRX) quarterly Change in Acquisitions & Divestments came in at $2.5 million in Q1 2025, down 61.6% quarter-over-quarter from $6.5 million in Q4 2024.
Lb Pharmaceuticals (LBRX) Change in Acquisitions & Divestments (2024 - 2025) Analysis & Trends
Lb Pharmaceuticals' Change in Acquisitions & Divestments history runs 2 years deep, the most recent figure standing at $2.5 million for Q1 2025.
- On a quarterly basis, Change in Acquisitions & Divestments changed N/A year-over-year to $2.5 million in Q1 2025; TTM through Mar 2026 was $9.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.5 million, down 89.43% from the prior year.
- Change in Acquisitions & Divestments retreated to $2.5 million in Q1 2025 per LBRX's latest filing, from $6.5 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $6.5 million in Q4 2024 and bottomed at $2.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn |
| 10 | Lb Pharmaceuticals | 990.01 Mn | 990.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.50 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | 6.51 Mn |
| Dec 31, 2024 | 6.51 Mn |